AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
No open-market purchases or sales by AgomAb Therapeutics NV insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in AgomAb Therapeutics NV as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +32 vs. Q4 2025
- Shares held
- 23.4M
- +23.4M vs. Q4 2025
- Total value
- $245.3M
- +$245.3M vs. Q4 2025
- New holders
- 32
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AGMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $337.0M |
| Q1 2026 | 32 | $245.3M |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding AgomAb Therapeutics NV; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | $53.9M | 5.28% | +5,141,992 | New |
| Sanofi | 2,783,096 | $29.2M | 8.69% | +2,783,096 | New |
| Cormorant Asset Management, LP | 2,465,348 | $25.9M | 1.30% | +2,465,348 | New |
| TCG Crossover Management, LLC | 2,053,233 | $21.5M | 0.62% | +2,053,233 | New |
| Federated Hermes, Inc. | 1,618,000 | $17.0M | 0.03% | +1,618,000 | New |
| Casdin Capital, LLC | 1,550,000 | $16.3M | 1.23% | +1,550,000 | New |
| Andera Partners | 1,538,702 | $16.1M | 9.12% | +1,538,702 | New |
| FMR LLC | 1,458,677 | $15.3M | 0.00% | +1,458,677 | New |
| Nantahala Capital Management, LLC | 1,200,000 | $12.9M | 0.80% | +1,200,000 | New |
| Standard Life Aberdeen plc | 707,656 | $7.42M | 0.01% | +707,656 | New |
| Perceptive Advisors LLC | 600,000 | $6.29M | 0.12% | +600,000 | New |
| Samsara BioCapital, LLC | 600,000 | $6.29M | 0.61% | +600,000 | New |
| Siren, L.L.C. | 411,250 | $4.31M | 0.12% | +411,250 | New |
| LMR Partners LLP | 300,000 | $3.15M | 0.03% | +300,000 | New |
| Seven Grand Managers, LLC | 200,000 | $2.10M | 0.14% | +200,000 | New |
| Redmile Group, LLC | 156,250 | $1.64M | 0.11% | +156,250 | New |
| Millennium Management LLC | 95,233 | $999.0K | 0.00% | +95,233 | New |
| Pfizer Inc | 75,000 | $813.8K | 0.34% | +75,000 | New |
| Alyeska Investment Group, L.P. | 75,000 | $786.8K | 0.00% | +75,000 | New |
| Laurion Capital Management LP | 50,000 | $524.5K | 0.05% | +50,000 | New |
| Bellevue Group AG | 50,000 | $524.5K | 0.01% | +50,000 | New |
| Sectoral Asset Management Inc | 43,500 | $477.3K | 0.40% | +43,500 | New |
| Goldman Sachs Group Inc | 35,739 | $374.9K | 0.00% | +35,739 | New |
| Citadel Advisors LLC | 35,000 | $367.1K | 0.00% | +35,000 | New |
| Burkehill Global Management, LP | 35,000 | $367.1K | 0.02% | +35,000 | New |
| HRT Financial LP | 23,726 | $248.0K | 0.00% | +23,726 | New |
| D. E. Shaw & Co., Inc. | 15,326 | $160.8K | 0.00% | +15,326 | New |
| Two Sigma Investments, LP | 14,241 | $149.4K | 0.00% | +14,241 | New |
| Jane Street Group, LLC | 12,794 | $134.2K | 0.00% | +12,794 | New |
| UBS Group AG | 6,437 | $67.5K | 0.00% | +6,437 | New |
| Morgan Stanley | 3,025 | $31.7K | 0.00% | +3,025 | New |
| SBI Securities Co., Ltd. | 2 | $21 | 0.00% | +2 | New |